2 results match your criteria: "University of Turin and San Giovanni Bosco Hospital[Affiliation]"
Efficacy of low or standard rituximab-based protocols and comparison to Ponticelli's regimen in membranous nephropathy.
J Nephrol
April 2021
CMID-Nephrology and Dialysis Unit (ERK-Net Member), Coordinating Center of the Network for Rare Diseases of Piedmont and Aosta Valley, University of Turin and San Giovanni Bosco Hospital, Piazza del Donatore di Sangue 3, 10054, Turin, Italy.
Background: Patients (pts) with primary Membranous nephropathy (MN) have an autoimmune disease caused by autoantibodies against podocyte antigens and 60-80% of them have antibodies directed against the M-type phospholipase A2 receptor (PLA2R). Immunosuppressive treatment is recommended in high-medium risk pts. Recently the use of rituximab (RTX), has emerged as an important therapeutic option in pts with primary MN.
View Article and Find Full Text PDF